In summary, although the molecular alteration responsible for the occurrence of GX in the gastric mucosa remains unclear, GX is a powerful marker for prediction of the development of synchronous/metachronous GC, at least compared with molecular alterations of MSI or methylation of hMLH1, CDKN2A or APC in patients with early GC. This evidence concerns the gene APC and gastric cancer.